drugset / Trial / NCT03794037
Montelukast for Prevention & Treatment of OHSS
RandomizedParallel-groupSingle-blindPrevention
Summary
montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.
Timeline
- Start
- 2018-12-05
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Montelukast | Other / unclassified | 10 mg | Oral |
| Comparator | Dydrogesterone | Other / unclassified | 10 mg | Oral |
| Comparator | dydrgesterone | Unknown | 10 mg | — |